Internal bleeding is a risk associated with all blood thinners, but some may be more dangerous than others. Thousands of people are claiming Xarelto, a popular new generation blood thinner, caused life-threatening or even deadly internal bleeding.
If you or a loved one suffered internal bleeding after taking Xarelto or a similar drug, the attorneys from Gacovino, Lake & Associates, P.C. are here to help you. Contact our office today at 631-600-0000 for a complimentary case consultation with a Xarelto bleeding lawsuit lawyer. We can help you understand your options for compensation, and you pay nothing unless we recover a payout on your behalf.
What Is the Issue with Xarelto and Other Similar Blood Thinners?
Xarelto is just one medication in a class called direct thrombin inhibitors. Xarelto hit the market in the United States in July 2011. Doctors prescribe these drugs to reduce the risk of strokes and blood clots. If you or a loved one has atrial fibrillation, deep vein thrombosis or pulmonary embolism, or has undergone a knee or hip replacement, your doctor may have prescribed this medication.
In many cases, doctors prescribe Xarelto instead of warfarin because it is easier to use, requiring only one pill each day, and no regular blood testing. Warfarin, better known by the brand name Coumadin, has been on the market for decades. However, patients must see their doctor regularly for testing to adjust the dosage and ensure the drug continues to work as intended.
While all blood thinners come with a risk of internal bleeding, there is an additional issue with Xarelto. Not only does it come with a bigger risk of bleeds, but there is also no antidote. Doctors can easily reverse the effects of warfarin with a dose of vitamin K. Without a similar antidote, internal bleeding in a patient taking Xarelto can quickly become a serious medical emergency.
Those who suffered internal bleeding while taking Xarelto claim the drug companies who manufacture and market the prescription medication misrepresented the safety record and risk of side effects associated with the drug. They also allege the company was aware of the potential for severe side effects (including death from bleeding) and did not adequately warn doctors and their patients of these risks.
Has the FDA Taken Action Against Xarelto?
According to a report by the Institute for Safe Medication Practices (ISMP), Xarelto has been associated with “serious, disabling or fatal injury,” including severe internal bleeding, leaving some patients hospitalized and even dead. The potential bleeding complications are so concerning that the U.S. Food and Drug Administration (FDA) mandated increasingly specific warning labels regarding the seriousness of possible bleeding and the lack of a reversal agent.
The FDA sent the makers of Xarelto a warning letter in 2013. This letter expressed concern over a print advertisement that minimized the potential for bleeding. They warned that the ad emphasized the benefits section without the same emphasis on the risks, making them seem unimportant or not serious. The letter also states the most common adverse effect of the drug is bleeding.
There is no consensus on whether Xarelto has a higher bleeding risk than other, older blood thinning medications.
Are There Any Lawsuits Pending Against Xarelto?
Patients and the families of victims have filed thousands of lawsuits against Bayer AG and Janssen Pharmaceuticals, the manufacturer (Bayer AG) and marketer (Johnson & Johnson’s Janssen Pharmaceuticals) of Xarelto.
These suits claim the drug companies failed to adequately warn doctors and their patients about the risks associated with the blood thinning medication. According to the 2017 annual report to the SEC, issued by the drug manufacturer’s parent company, there were 16,900 pending Xarelto lawsuits at the close of 2016.
Courts consolidated all cases filed at the federal level into a multidistrict litigation in the United States District Court for the Eastern District of Louisiana. As of October 2017, the MDL is in bellwether trials.
The first three heard in the Eastern District of Louisiana ended with verdicts in favor of the defense. The juries in those cases decided the warnings issued on the medication inserts and other information about the drug showed a strong enough emphasis on the bleeding risk.
A fourth bellwether trial is on the calendar for January 2018 in Texas. Once these four bellwether trials conclude, all the remaining cases in the MDL will return to their original jurisdictions for trial if necessary. While the bellwether trials have no legal impact on these remaining cases, they do inform all parties about the strength of their cases and offer a potential outcome. We will continue to fight for the compensation our clients deserve, no matter the outcome of the bellwether cases.
A Philadelphia judge has also organized many of the cases filed at the state level into an MDL.
Even though these MDLs are already well underway, additional plaintiffs continue to file their cases. If you believe you may qualify for compensation based on injuries you suffered from a Xarelto-related bleed, we can help you evaluate the facts of your case and possibly file a claim on your behalf.
How Can I Talk to a Xarelto Bleeding Lawsuit Lawyer?
At Gacovino, Lake & Associates, P.C., our multidistrict litigation attorneys can help you navigate the process of filing your case and fighting for the compensation you deserve. Call us today at 631-600-0000 for a free case evaluation with one of our Xarelto bleeding lawsuit attorneys.